Last reviewed · How we verify
OPC-41061 （Tolvaptan)
Tolvaptan is a selective, competitive antagonist of the vasopressin V2 receptor.
Tolvaptan is a selective, competitive antagonist of the vasopressin V2 receptor. Used for Hyponatremia in hospitalized patients, Autosomal dominant polycystic kidney disease (ADPKD).
At a glance
| Generic name | OPC-41061 （Tolvaptan) |
|---|---|
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Drug class | Vasopressin V2 receptor antagonist |
| Target | Vasopressin V2 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By blocking the V2 receptor, tolvaptan reduces water reabsorption in the kidneys, thereby increasing urine production and reducing fluid overload in patients with heart failure and hyponatremia.
Approved indications
- Hyponatremia in hospitalized patients
- Autosomal dominant polycystic kidney disease (ADPKD)
Common side effects
- Headache
- Diarrhea
- Nausea
- Fatigue
- Dizziness